COCH
Envoy Medical, Inc.
Medical - Devices
Market Cap$14M
5Y Perf.-93.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
COCH vs MDT
Revenue, margins, valuation, and 5-year total return — side by side.
MDT
Medtronic plc
Medical - Devices
Market Cap$99.94B
5Y Perf.-41.8%
COCH vs MDT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | COCH | MDT |
|---|---|---|
| Industry | Medical - Devices | Medical - Devices |
| Market Cap | $14M | $99.94B |
| Revenue (TTM) | $241K | $35.48B |
| Net Income (TTM) | $-24M | $4.61B |
| Gross Margin | -262.7% | 61.9% |
| Operating Margin | -92.4% | 17.9% |
| Forward P/E | — | 13.8x |
| Total Debt | $919K | $28.52B |
| Cash & Equiv. | $4M | $2.22B |
COCH vs MDT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
COCH
MDT
| Stock | Apr 21 | May 26 | Return |
|---|---|---|---|
| Envoy Medical, Inc. (COCH) | 100 | 6.5 | -93.5% |
| Medtronic plc (MDT) | 100 | 58.2 | -41.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: COCH vs MDT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MDT leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Envoy Medical, Inc. is the stronger pick specifically for growth and revenue expansion and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
COCH
Envoy Medical, Inc.
The Growth Play
COCH is the clearest fit if your priority is growth exposure.
- Rev growth 7.1%, EPS growth 17.4%, 3Y rev CAGR 0.6%
- 7.1% revenue growth vs MDT's 3.6%
- 14.1% yield, vs MDT's 3.6%
Best for: growth exposure
MDT
Medtronic plc
The Income Pick
MDT carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 36 yrs, beta 0.47, yield 3.6%
- 26.5% 10Y total return vs COCH's -93.2%
- Lower volatility, beta 0.47, Low D/E 59.1%, current ratio 1.85x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | COCH | 7.1% revenue growth vs MDT's 3.6% |
| Quality / Margins | MDT | 13.0% margin vs COCH's -98.6% |
| Stability / Safety | MDT | Beta 0.47 vs COCH's 0.90 |
| Dividends | COCH | 14.1% yield, vs MDT's 3.6% |
| Momentum (1Y) | MDT | -2.8% vs COCH's -56.6% |
| Efficiency (ROA) | MDT | 175.8% ROA vs COCH's -256.7% |
COCH vs MDT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
COCH vs MDT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMDTLAGGINGCOCH
COCHEnvoy Medical, Inc.
0leads
MDTMedtronic plc
4leads
6 Total Categories
CATEGORYLEADERvs COCHMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MDT4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MDT4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
MDT5/6
Risk & VolatilityBeta, volatility, and downside exposure
MDT2/2
Analyst OutlookRatings, price targets, and dividends
Tied
—
Income & Cash Flow (Last 12 Months)
MDT leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT is the larger business by revenue, generating $35.5B annually — 147236.5x COCH's $241,000. MDT is the more profitable business, keeping 13.0% of every revenue dollar as net income compared to COCH's -98.6%. On growth, COCH holds the edge at +78.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | COCHEnvoy Medical, In… | MDTMedtronic plc |
|---|---|---|
| RevenueTrailing 12 months | $241,000 | $35.5B |
| EBITDAEarnings before interest/tax | -$22M | $9.4B |
| Net IncomeAfter-tax profit | -$24M | $4.6B |
| Free Cash FlowCash after capex | -$18M | $5.4B |
| Gross MarginGross profit ÷ Revenue | -2.6% | +61.9% |
| Operating MarginEBIT ÷ Revenue | -92.4% | +17.9% |
| Net MarginNet income ÷ Revenue | -98.6% | +13.0% |
| FCF MarginFCF ÷ Revenue | -76.3% | +15.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +78.6% | +8.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +25.0% | -11.9% |
MDT leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — COCH and MDT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | COCHEnvoy Medical, In… | MDTMedtronic plc |
|---|---|---|
| Market CapShares × price | $14M | $99.9B |
| Enterprise ValueMkt cap + debt − cash | $11M | $126.2B |
| Trailing P/EPrice ÷ TTM EPS | -0.54x | 21.60x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 13.80x |
| PEG RatioP/E ÷ EPS growth rate | — | 35.17x |
| EV / EBITDAEnterprise value multiple | — | 14.32x |
| Price / SalesMarket cap ÷ Revenue | 56.96x | 2.98x |
| Price / BookPrice ÷ Book value/share | — | 2.08x |
| Price / FCFMarket cap ÷ FCF | — | 19.28x |
Evenly matched — COCH and MDT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
MDT leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), MDT scores 6/9 vs COCH's 3/9, reflecting solid financial health.
| Metric | COCHEnvoy Medical, In… | MDTMedtronic plc |
|---|---|---|
| ROE (TTM)Return on equity | — | +9.4% |
| ROA (TTM)Return on assets | -2.6% | +175.8% |
| ROICReturn on invested capital | — | +6.0% |
| ROCEReturn on capital employed | -44.7% | +7.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 |
| Debt / EquityFinancial leverage | — | 0.59x |
| Net DebtTotal debt minus cash | -$3M | $26.3B |
| Cash & Equiv.Liquid assets | $4M | $2.2B |
| Total DebtShort + long-term debt | $919,000 | $28.5B |
| Interest CoverageEBIT ÷ Interest expense | -5.74x | 9.08x |
MDT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
MDT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MDT five years ago would be worth $7,230 today (with dividends reinvested), compared to $678 for COCH. Over the past 12 months, MDT leads with a -2.8% total return vs COCH's -56.6%. The 3-year compound annual growth rate (CAGR) favors MDT at -1.4% vs COCH's -59.7% — a key indicator of consistent wealth creation.
| Metric | COCHEnvoy Medical, In… | MDTMedtronic plc |
|---|---|---|
| YTD ReturnYear-to-date | -5.2% | -18.1% |
| 1-Year ReturnPast 12 months | -56.6% | -2.8% |
| 3-Year ReturnCumulative with dividends | -93.5% | -4.2% |
| 5-Year ReturnCumulative with dividends | -93.2% | -27.7% |
| 10-Year ReturnCumulative with dividends | -93.2% | +26.5% |
| CAGR (3Y)Annualised 3-year return | -59.7% | -1.4% |
MDT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
MDT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MDT is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than COCH's 0.90 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MDT currently trades 73.3% from its 52-week high vs COCH's 34.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | COCHEnvoy Medical, In… | MDTMedtronic plc |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.95x | 0.42x |
| 52-Week HighHighest price in past year | $1.91 | $106.33 |
| 52-Week LowLowest price in past year | $0.36 | $77.16 |
| % of 52W HighCurrent price vs 52-week peak | +34.6% | +73.3% |
| RSI (14)Momentum oscillator 0–100 | 47.9 | 27.3 |
| Avg Volume (50D)Average daily shares traded | 235K | 7.8M |
MDT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Evenly matched — COCH and MDT each lead in 1 of 2 comparable metrics.
Analyst Outlook
For income investors, COCH offers the higher dividend yield at 14.06% vs MDT's 3.57%.
| Metric | COCHEnvoy Medical, In… | MDTMedtronic plc |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $109.50 |
| # AnalystsCovering analysts | — | 49 |
| Dividend YieldAnnual dividend ÷ price | +14.1% | +3.6% |
| Dividend StreakConsecutive years of raises | 0 | 36 |
| Dividend / ShareAnnual DPS | $0.09 | $2.78 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.2% |
Evenly matched — COCH and MDT each lead in 1 of 2 comparable metrics.
Key Takeaway
MDT leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallMedtronic plc (MDT)Leads 4 of 6 categories
Loading custom metrics...
COCH vs MDT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is COCH or MDT a better buy right now?
For growth investors, Envoy Medical, Inc.
(COCH) is the stronger pick with 7. 1% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Medtronic plc (MDT) a "Buy" — based on 49 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — COCH or MDT?
Over the past 5 years, Medtronic plc (MDT) delivered a total return of -27.
7%, compared to -93. 2% for Envoy Medical, Inc. (COCH). Over 10 years, the gap is even starker: MDT returned +24. 3% versus COCH's -93. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — COCH or MDT?
By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.
42β versus Envoy Medical, Inc. 's 0. 95β — meaning COCH is approximately 124% more volatile than MDT relative to the S&P 500.
04Which is growing faster — COCH or MDT?
By revenue growth (latest reported year), Envoy Medical, Inc.
(COCH) is pulling ahead at 7. 1% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: Medtronic plc grew EPS 30. 8% year-over-year, compared to 17. 4% for Envoy Medical, Inc.. Over a 3-year CAGR, MDT leads at 1. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — COCH or MDT?
Medtronic plc (MDT) is the more profitable company, earning 13.
9% net margin versus -98. 6% for Envoy Medical, Inc. — meaning it keeps 13. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDT leads at 17. 8% versus -92. 4% for COCH. At the gross margin level — before operating expenses — MDT leads at 65. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — COCH or MDT?
All stocks in this comparison pay dividends.
Envoy Medical, Inc. (COCH) offers the highest yield at 14. 1%, versus 3. 6% for Medtronic plc (MDT).
07Is COCH or MDT better for a retirement portfolio?
For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
42), 3. 6% yield). Both have compounded well over 10 years (MDT: +24. 3%, COCH: -93. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between COCH and MDT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(COCH: 78.6% · MDT: 8.8%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.